Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer

Mostrar otras versiones (1)

Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spalt‐like tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Liping, Lin, Chuyong, Wang, Xi, Li, Qiji, Li, Yue, Wang, Meng, Zhao, Zekun, Wu, Xianqiu, Shi, Dongni, Xiao, Yunyun, Ren, Liangliang, Jian, Yunting, Yang, Meisongzhu, Ou, Ruizhang, Deng, Guangzheng, Ouyang, Ying, Chen, Xiangfu, Li, Jun, Song, Libing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895605/
https://www.ncbi.nlm.nih.gov/pubmed/31657150
http://dx.doi.org/10.15252/emmm.201910638
Mostrar todas las versiones(2)

Ejemplares similares